FBCC (@biotechport) 's Twitter Profile
FBCC

@biotechport

Only my thoughts/ideas. I may be Long or Short the names I am Tweeting about. My Tweets are not investment recommendations. Retweets do not equal endorsement.

ID: 780646751963230208

calendar_today27-09-2016 05:54:24

2,2K Tweet

2,2K Followers

767 Following

FBCC (@biotechport) 's Twitter Profile Photo

$OCUL So if you give AXPXLI you will need to monitor who are those 17% of patients that have slow BCVA loss then the others. You will anyway need to come to the office often for monitoring. So how does it help patients with less burden? Instead, you can administrate HD Eylea

FBCC (@biotechport) 's Twitter Profile Photo

$OCUL Dodging the answer on the presenting of BCVA ITT population chart. "We will "maybe" show it"... "Lets talk about CSFT instead"... "But look how great out non-rescue patient data"

FBCC (@biotechport) 's Twitter Profile Photo

$OCUL TKI is a supper weak approach. It i supposed to be at supratherapeutic concentration in the eye for 4-6 months and yet its barely show any benefit over a drug with 7-10d half life.

FBCC (@biotechport) 's Twitter Profile Photo

I doubt Iran can do anything against US naval superiority. Funny thing though, if they do sink US ship, Trump will just erase them. Trump is not Carter, he will double down.

Even (@ttramyloid) 's Twitter Profile Photo

Safety is what killed the gene therapies for wet AMD. The safety for $ocul is very poor. The company is probably worthless imo.

FBCC (@biotechport) 's Twitter Profile Photo

$OCUL The claim that their drug "proved superior" to Eylea is ridiculous. Marginal % difference on responders would mean something if the whole Eylea treatment would be one injection. But its what? 6-8 injections to get to max therapeutic effect. So what exactly did you show in

FBCC (@biotechport) 's Twitter Profile Photo

Israel was doing whatever they wanted in Iranian sky for a couple of weeks and those mullahs fks couldn't do anything. US is going to roll over them without even noticing.

AT (@biosyncopation) 's Twitter Profile Photo

$VIR EV @ ~$500 post +65% move. $JANX was @ ~$2.5B EV at peak. I'd argue that VIR is currently at a better position than JANX was at peak, competition wise, and with a better molecule. Even if you discount valuation by half due to partnership, there's still +$1-1.5B to add.

$VIR  EV @ ~$500 post +65% move. $JANX was @ ~$2.5B EV at peak. I'd argue that VIR is currently at a better position than JANX was at peak, competition wise, and with a better molecule. Even if you discount valuation by half due to partnership, there's still +$1-1.5B to add.
FBCC (@biotechport) 's Twitter Profile Photo

$FULC Data looks strong. See no holes in it. ~20% HbF in 12w (this is not the peak as the trajectory is still going up). More than doubled in % in HbF sells. Decrease in all hemolysis markers. Hemoglobin increase of 1.1 g/dL in 12w. The main effect of the drug will kick in

FBCC (@biotechport) 's Twitter Profile Photo

$FULC I rarely say shit like that. Falling knives is not my favorite play. But this move is stupid. They have a real drug, enough cash and EV of ~200MM. One of the best r/r in biotech today.